(Anti-autoimmune disease antibody drugs)
SBI-9674 are antibody drug candidates for autoimmune diseases, especially aiming for the treatment such as SLE (Systemic Lupus Erythematosus).
SLE is an autoimmune disease in which the over-activated immune system mistakenly attacks its own healthy tissues and organs. It can affect the skin, joints, kidneys, brain, and other organs. In Japan it is designated as an intractable disease. Over-activation of pDCs and B cells is considered as major cause of SLE.
Mode of action
Anti-SBI9674 antibody binds to pDCs.
The antibody suppresses overproduction of IFNα through its binding to SBI9674 protein on pDCs. As this antibody can inhibit IFNα production without killing pDCs, it can also be applied to the patients with weak in cytotoxicity induced by antibody drugs.